Welcome to our dedicated page for Rigel Pharmaceuticals news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a commercial stage biotechnology company based in South San Francisco, California, focused on therapies for hematologic disorders and cancer. This news page aggregates company announcements, financial updates and clinical data disclosures so readers can follow Rigel’s progress across its marketed products and development pipeline.
Rigel’s news flow frequently covers net product sales and total revenue from its hematology and oncology portfolio, including TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib). Press releases detail quarterly and preliminary annual revenue, contract revenues from collaborations and government contracts, and commentary from management on commercial execution and financial performance.
Clinical and regulatory milestones are another major focus of Rigel’s news. Updates describe Phase 1b data for the investigational IRAK1/4 dual inhibitor prodrug R289 in relapsed or refractory lower-risk myelodysplastic syndrome, including safety, tolerability, pharmacokinetics and measures such as red blood cell transfusion independence. The company also reports on long-term and real-world data for REZLIDHIA in mIDH1 acute myeloid leukemia, and on presentations of pralsetinib data in RET fusion-positive solid tumors at oncology conferences.
Rigel’s releases highlight participation in scientific and investor meetings, such as the American Society of Hematology Annual Meeting and Exposition, the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium, and major healthcare investment conferences. Corporate news can also include collaboration updates, such as developments in the ocadusertib program with Eli Lilly and Company, and stock-based inducement grants under Nasdaq Listing Rule 5635(c)(4).
Investors, clinicians and researchers can use this RIGL news feed to monitor earnings announcements, pipeline readouts, regulatory designations and conference presentations that shape the company’s trajectory in hematology and oncology.
Rigel Pharmaceuticals (RIGL) will announce its Q1 2022 financial results on May 3, 2022, followed by an investor call at 4:30 PM ET. Dr. Caroline Piatek, a Key Opinion Leader and FORWARD trial investigator, will present insights on warm autoimmune hemolytic anemia (wAIHA) treatment and the potential role of fostamatinib. The ongoing Phase 3 trial evaluates fostamatinib against a placebo in 90 patients who have not responded to prior treatments. Topline data is expected mid-2022. Fostamatinib holds Orphan Drug and Fast Track designations from the FDA.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) granted stock options totaling 626,000 shares to 15 new employees. The options, approved by Rigel's Compensation Committee, were issued as part of the Inducement Plan and have an exercise price of $3.10 per share. Vesting will occur immediately upon achieving performance conditions or over four years, with one-fourth vesting annually. This announcement complies with NASDAQ Listing Rule 5635(c)(4), aiming to incentivize new hires.
Rigel Pharmaceuticals announced the publication of Phase 2 clinical study data on fostamatinib for treating warm antibody autoimmune hemolytic anemia (wAIHA) in the American Journal of Hematology. The study showed that 50% of treated patients achieved significant hemoglobin increases, indicating potential as a first approved therapy for wAIHA. Fostamatinib is also recognized with Orphan Drug and Fast Track designations by the FDA. The company aims for regulatory approval in 2023, as no targeted therapies currently exist for wAIHA patients.
Rigel Pharmaceuticals (RIGL) reported its fourth-quarter and full-year 2021 financial results, highlighting a net loss of $22.6 million for Q4 and $17.9 million for the year. Q4 revenues were $20.4 million, a slight decline in TAVALISSE sales. The company completed enrollment for two pivotal Phase 3 trials in autoimmune conditions and COVID-19, with results expected mid-2022. Rigel aims to expand TAVALISSE's market to include warm autoimmune hemolytic anemia (wAIHA) and COVID-19, potentially increasing its product offerings.
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) will report its fourth quarter and year-end 2021 financial results on March 1, 2022, after market close. A live conference call and webcast will follow at 4:30 PM ET for management to discuss the results and provide business updates. Rigel, known for its TAVALISSE product, focuses on developing drugs for hematologic disorders and rare diseases. The company is also conducting various clinical trials for treatments in autoimmune and COVID-19-related conditions.
Rigel Pharmaceuticals will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 10:30 a.m. ET. CEO Raul Rodriguez will provide a comprehensive overview of the company.
Interested parties can access the live webcast on Rigel's website. Rigel focuses on novel small molecule drugs for various diseases, with its FDA-approved product TAVALISSE for chronic immune thrombocytopenia.
The company is also progressing in clinical trials for multiple conditions, including COVID-19 and autoimmune diseases.
Rigel Pharmaceuticals (Nasdaq: RIGL) provided a business update on January 10, 2022, highlighting a preliminary total revenue of approximately $20.4 million for Q4 2021. The company reported 6,787 bottles of TAVALISSE sold in 2021, up 8% from 2020. Rigel is advancing its clinical pipeline, including a Phase 3 trial in warm autoimmune hemolytic anemia (wAIHA) and a COVID-19 study, with topline data expected in mid-2022. The company also expects cash reserves of about $124.9 million as of year-end 2021, a significant increase from $57.3 million in 2020.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced the grant of stock options for 610,000 shares to 14 new employees, effective January 6, 2022. This grant, approved by the Compensation Committee, aligns with NASDAQ Listing Rule 5635(c)(4). The options feature an exercise price of $2.62 per share and will vest over four years. Rigel, dedicated to developing treatments for hematologic disorders and rare diseases, continues its clinical trials for products like TAVALISSE, currently investigating treatments for conditions including autoimmune hemolytic anemia and COVID-19.
Rigel Pharmaceuticals announced positive topline results from its collaboration with Kissei Pharmaceutical, revealing that fostamatinib significantly outperformed placebo in a Phase 3 clinical trial for chronic immune thrombocytopenia (ITP) in Japan. The trial involved 34 patients, with successful platelet responses defined as ≥50,000 platelets per μL on four of the last six visits. The safety profile was consistent with prior studies. Fostamatinib, sold as TAVALISSE in the U.S., has Orphan Drug Designation in Japan and offers potential new treatment options for approximately 17,000 ITP patients.
Rigel Pharmaceuticals has appointed Kamil Ali-Jackson to its Board of Directors, effective January 3, 2022. Ali-Jackson brings nearly 40 years of experience in the biopharmaceutical sector, with a focus on licensing and M&A transactions. She currently serves as chief legal officer at Aclaris Therapeutics, which she co-founded.
CEO Raul Rodriguez praised her extensive background, emphasizing its potential to enhance Rigel's growth in hematology, oncology, and immunology therapies. Rigel is known for its drug TAVALISSE, aimed at treating chronic immune thrombocytopenia.